NEWS RELEASES
YEAR
-
CANbridge Receives Approval to Commence CAN008 Phase II/III Trial in Glioblastoma Multiforme (GBM) in China
APR 12, 2018
-
Industry Veteran Joins CANbridge Life Sciences Advisory Team
FEB 13, 2018
-
Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China
FEB 02, 2018
-
CANbridge Appoints Sunny Zhang as Vice President of Regulatory Affairs and Quality
JAN 16, 2018
-
CANbridge Life Sciences Submits Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) In China
DEC 21, 2017
-
CANbridge Completes Patient Enrolment for Phase I Clinical Trial of CAN008 in Treatment of Glioblastoma Multiforme in Taiwan
NOV 30, 2017
-
CAN008 Injection for the treatment of GBM China Taiwan Phase I Data releasing
NOV 02, 2017
-
James Xue is Appointed to Leadership and Development Council Member
SEP 26, 2017
-
CANbridge Life Sciences Appoints Chief Business Officer Will Head First US Office
SEP 12, 2017
-
CANBRIDGE CONGRATULATES APOGENIX APG101 RECEIVING EMA “PRIME” DESIGNATION
JUL 26, 2017
